Global Retirement Partners LLC Purchases 1,991 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Global Retirement Partners LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 41.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,744 shares of the biopharmaceutical company’s stock after buying an additional 1,991 shares during the quarter. Global Retirement Partners LLC’s holdings in Gilead Sciences were worth $580,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in GILD. State Street Corp lifted its holdings in Gilead Sciences by 2.6% in the 2nd quarter. State Street Corp now owns 59,317,162 shares of the biopharmaceutical company’s stock worth $4,571,574,000 after purchasing an additional 1,514,894 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Gilead Sciences by 324.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares during the last quarter. Morgan Stanley lifted its holdings in Gilead Sciences by 11.5% in the 4th quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock worth $1,476,358,000 after purchasing an additional 1,780,489 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Gilead Sciences by 70.6% in the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after purchasing an additional 6,410,047 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Gilead Sciences by 14.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 15,421,436 shares of the biopharmaceutical company’s stock worth $951,350,000 after purchasing an additional 1,987,058 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Mizuho reduced their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Cantor Fitzgerald cut their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Wells Fargo & Company cut their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Finally, Barclays cut their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $85.36.

Check Out Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Price Performance

Gilead Sciences stock opened at $72.88 on Tuesday. The business’s 50-day simple moving average is $74.57 and its 200 day simple moving average is $77.24. The stock has a market cap of $90.74 billion, a price-to-earnings ratio of 16.20, a P/E/G ratio of 0.93 and a beta of 0.19. Gilead Sciences, Inc. has a 12-month low of $71.37 and a 12-month high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. Gilead Sciences’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.67 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a $0.77 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 4.23%. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the transaction, the chief financial officer now owns 101,534 shares of the company’s stock, valued at $8,709,586.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the sale, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,242 shares of company stock valued at $1,277,726. 0.21% of the stock is currently owned by company insiders.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.